Top

Journal of Assisted Reproduction and Genetics

Published in:

01-02-2014 | Genetics

Analyzing the possible involvement of anti-Müllerian hormone and anti-Müllerian hormone receptor II single nucleotide polymorphism in infertility

Authors: Yoko Yoshida, Yoshiki Yamashita, Natsuho Saito, Yoshihiro Ono, Hikaru Yamamoto, Yoko Nakamura, Atsushi Hayashi, Yoshito Terai, Masahide Ohmichi

Published in: Journal of Assisted Reproduction and Genetics | Issue 2/2014

Abstract

Purpose

We performed TaqMan genotyping assays of anti-Mullerian hormone (AMH) and anti-Mullerian hormone receptor type II (AMHRII) single nucleotide polymorphisms (SNPs) in order to investigate how their frequency and distribution affect infertility treatment outcome.

Methods

Eighty Japanese women (advanced age: n = 51, endometriosis: n = 18, male infertility as a control: n = 11) who undertook ART were included in the study, and all couples underwent a full infertility investigation protocol. In order to investigate the natural distribution of SNPs, a naturally pregnant group of 28 subjects was recruited from among women who conceived naturally and subsequently delivered in our department. Genomic DNA was extracted from peripheral blood and genotyping was conducted by TaqMan genotyping assay. The relationship of AMH and AMHRII SNPs and treatment outcome in infertile women. Comparison of allele and genotype frequencies of infertile patients with naturally pregnant women.

Results

AMHRII −482 A>G homozygote mutation was complicated with ISV 5–6 C>T homozygote mutation and showed a significantly lower oocyte retrieval rate compared with a wild type. Two of 3 cases of AMHRII −482 A>G homozygote mutation were poor responders, and the distribution and frequency of each allele of naturally pregnant women showed no statistical difference compared with infertile women.

Conclusions

This study revealed the possible involvement of AMHRII −482 A>G polymorphism on the malfunction of follicular development in Japanese women.

van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83:979–87.PubMedCrossRef

Peñarrubia J, Fábregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist—gonadotropin treatmen. Hum Reprod. 2005;20:915–22.PubMedCrossRef

Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril. 2006;85:1541–3.PubMedCrossRef

La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22:766–71.PubMedCrossRef

Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles–implications for individualization of therapy. Hum Reprod. 2007;22:2414–21.PubMedCrossRef

Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012;27:594–608.PubMedCrossRef

Karita M, Yamashita Y, Hayashi A, Yoshida Y, Hayashi M, Yamamoto H, et al. Influence of severe endometriosis on gene expression of progesterone receptor in granulosa cells in vitro fertilization-embryo transfer. Fertil Steril. 2011;95:889–94.PubMedCrossRef

di Clemente N, Josso N, Gouédard L, Belville C. Components of the anti-Müllerian hormone signaling pathway in gonads. Mol Cell Endocrinol. 2003;211:9–14.PubMedCrossRef

Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling. Mol Endocrinol. 2001;15:936–45.PubMed

10.

Visser JA, Themmen AP. Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234:81–6.PubMedCrossRef

11.

Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.PubMedCrossRef

12.

Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142:4891–9.PubMed

13.

Kevenaar ME, Thermmen APN, Rivadeneria F, Uitterlinden AG, Laven JSE, van Schoor NM, et al. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod. 2007;22:2382–8.PubMedCrossRef

14.

Grootegoed JA, Baarends WM, Themmen AP. Welcome to the family: the anti-müllerian hormone receptor. Mol Cell Endocrinol. 1994;100:29–34.PubMedCrossRef

15.

Josso N, Rey R, Picard JY. Testicular anti-Müllerian hormone: clinical applications in DSD. Semin Reprod Med. 2012;5:364–73.

16.

Kevenaar ME, Themmen AP, Laven JS, Sonntag B, Fong SL, Uitterlinden AG, et al. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod. 2007;22:1547–54.PubMedCrossRef

17.

Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18(1):71–106.PubMed

18.

Mulders AG, Laven JS, Imani B, Eijkemans MJ, Fauser BC. IVF outcome in anovulatory infertility (WHO group 2)–including polycystic ovary syndrome–following previous unsuccessful ovulation induction. Reprod Biomed Online. 2003;7:50–8.PubMedCrossRef

19.

Schug J, Overton GC. Modeling transcription factor binding sites with Gibbs Sampling and Minimum Description Length encoding. Proc Int Conf Intell Syst Mol Biol. 1997;5:2.

Title: Analyzing the possible involvement of anti-Müllerian hormone and anti-Müllerian hormone receptor II single nucleotide polymorphism in infertility
Authors: Yoko Yoshida
Yoshiki Yamashita
Natsuho Saito
Yoshihiro Ono
Hikaru Yamamoto
Yoko Nakamura
Atsushi Hayashi
Yoshito Terai
Masahide Ohmichi
Publication date: 01-02-2014
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 2/2014
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-013-0134-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Analyzing the possible involvement of anti-Müllerian hormone and anti-Müllerian hormone receptor II single nucleotide polymorphism in infertility

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Apolipoprotein E (Apo E) gene polymorphisms and recurrent pregnancy loss: a meta-analysis

Are zona pellucida genes involved in recurrent oocyte lysis observed during in vitro fertilization?

A randomized controlled trial comparing two vitrification methods versus slow-freezing for cryopreservation of human cleavage stage embryos

Variants in DPF3 and DSCAML1 are associated with sperm morphology

A comparative cytogenetic study of miscarriages after IVF and natural conception in women aged under and over 35 years

Resveratrol treatment during goat oocytes maturation enhances developmental competence of parthenogenetic and hand-made cloned blastocysts by modulating intracellular glutathione level and embryonic gene expression